Cerebrospinal fluid neurofilament heavy protein levels associated with domain-specific cognitive decline in Alzheimer’s disease
- 1Department of Psychiatry, Wenzhou Seventh People’s Hospital, Wenzhou, Zhejiang, China
- 2Department of Psychiatry, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China
- 3Department of Medical Ultrasound, Wenzhou Key Laboratory of Interventional Ultrasound for Intelligent Healthcare and Clinical Translation, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Abstract
Background: Neurofilament proteins are fluid biomarkers of neuroaxonal damage in various neurological diseases. However, it remains to be elucidated whether CSF neurofilament heavy (NfH) protein levels correlate with cognitive decline and progression in Alzheimer’s disease (AD).
Methods: This study included 165 cognitively unimpaired (CU) participants, 385 participants with mild cognitive impairment (MCI), and 128 participants with AD. To examine correlations between CSF NfH levels and baseline cognitive measures, Pearson’s correlation was used. Linear mixed-effects models were fitted to assess the relationship between elevated CSF NfH levels and longitudinal cognitive decline in the CU, MCI and AD groups. Kaplan–Meier survival analyses and Cox proportional hazards models were used to assess the clinical progression in the CU and MCI groups separately.
Results: In the MCI group, higher CSF NfH levels were significantly associated with poorer performance across global measures (MMSE, CDR-SB, ADAS-Cog-13, and RAVLT immediate recall; p < 0.001) and three cognitive domains (such as memory, language, and executive function), in both cross-sectional and longitudinal analyses. In contrast, the significant associations in the CU and AD groups were observed for a subset of cognitive tests and domains. Kaplan–Meier survival analyses showed that the high CSF NfH group had higher progression rates than the low group in both the CU and MCI groups. In the Cox proportional hazards models, baseline CSF NfH (continuous) remained a significant predictor of clinical progression.
Discussion: Higher CSF NfH levels were associated with faster cognitive decline and clinical progression in CU and MCI groups but not in participants with AD, suggesting its potential as a biomarker for tracking early disease progression and cognitive impairment.
Related
- Cerebrospinal Fluid Myeloperoxidase Is Associated With Putamen Volume Beyond Neurofilament Light in Huntington's Disease
- Air pollution is associated with sex‐specific longitudinal changes in astrocytic and neuroinflammatory processes linked to cognitive decline in Alzheimer's disease at‐risk individuals
- Plasma Neurofilament Light Chain as a Complementary Biomarker for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.
- Sex‐specific brain reserve and progression from mild cognitive impairment to Alzheimer's disease dementia
- Targeting Specific Sirtuin Modulation: Emerging Therapeutic Strategies for Healthy Cognitive Ageing and Potential Implications for Alzheimer’s Disease
BibTeX
@article{zhang2026cerebrospinal,
title = {{Cerebrospinal fluid neurofilament heavy protein levels associated with domain-specific cognitive decline in Alzheimer’s disease}},
author = {Jianjing Zhang and Xiwu Wang and Lingkai Yang and Zhaoting Lv and Suilin Jia and Teng Ye},
journal = {Frontiers in Aging Neuroscience},
year = {2026},
month = oct,
doi = {10.3389/fnagi.2026.1826215},
url = {https://doi.org/10.3389/fnagi.2026.1826215},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cerebrospinal fluid neurofilament heavy protein levels associated with domain-specific cognitive decline in Alzheimer’s disease
AU - Jianjing Zhang
AU - Xiwu Wang
AU - Lingkai Yang
AU - Zhaoting Lv
AU - Suilin Jia
AU - Teng Ye
PY - 2026
DA - 2026/10/22
JO - Frontiers in Aging Neuroscience
DO - 10.3389/fnagi.2026.1826215
UR - https://doi.org/10.3389/fnagi.2026.1826215
AB - Background: Neurofilament proteins are fluid biomarkers of neuroaxonal damage in various neurological diseases. However, it remains to be elucidated whether CSF neurofilament heavy (NfH) protein levels correlate with cognitive decline and progression in Alzheimer’s disease (AD). Methods: This study included 165 cognitively unimpaired (CU) participants, 385 participants with mild cognitive impairment (MCI), and 128 participants with AD. To examine correlations between CSF NfH levels and baseline cognitive measures, Pearson’s correlation was used. Linear mixed-effects models were fitted to assess the relationship between elevated CSF NfH levels and longitudinal cognitive decline in the CU, MCI and AD groups. Kaplan–Meier survival analyses and Cox proportional hazards models were used to assess the clinical progression in the CU and MCI groups separately. Results: In the MCI group, higher CSF NfH levels were significantly associated with poorer performance across global measures (MMSE, CDR-SB, ADAS-Cog-13, and RAVLT immediate recall; p < 0.001) and three cognitive domains (such as memory, language, and executive function), in both cross-sectional and longitudinal analyses. In contrast, the significant associations in the CU and AD groups were observed for a subset of cognitive tests and domains. Kaplan–Meier survival analyses showed that the high CSF NfH group had higher progression rates than the low group in both the CU and MCI groups. In the Cox proportional hazards models, baseline CSF NfH (continuous) remained a significant predictor of clinical progression. Discussion: Higher CSF NfH levels were associated with faster cognitive decline and clinical progression in CU and MCI groups but not in participants with AD, suggesting its potential as a biomarker for tracking early disease progression and cognitive impairment.
SN - 1663-4365
ER -